Dear California Health Care Provider,
Given recent changes in epidemiology, CDPH is shifting recommendations for clade I mpox. See key messages followed by situational summary below.
Key Messages for health care providers:
- Any positive orthopoxvirus (OPXV), non-variola orthopoxvirus (NVO), or monkeypox virus (MPXV) result is sufficient for diagnosis of mpox.
- Expedited clade-specific testing is no longer indicated
- Suspected or confirmed clade I mpox may be managed similar to clade IIb mpox
- Advise patients with mpox to continue isolation and extra household precautions until the rash has totally healed.
- Recommend two doses of mpox vaccine for patients at risk; this includes immune compromised individuals and for use as post exposure prophylaxis within 14 days of exposure.
- Notify your local health department if you identify atypical transmission dynamics (e.g., different affected populations, occupational healthcare transmission) or any mpox-related deaths or ICU admissions.
Situation summary: There has been a recent increase in clade Ib mpox cases in California and the US. Recent public health data suggests a likely transition towards sustained community transmission of clade Ib mpox within California and the US (CDC). Additional cases of both travel-related and domestically-acquired cases of clade Ib mpox are expected. At this time, clade Ib mpox disease severity and transmission dynamics are appearing largely similar to clade IIb mpox. Risk for severe disease from either clade of mpox is highest for people who are immunocompromised. Vaccination with two doses of JYNNEOS vaccine remains the best tool to reduce risk of infection and prevent severe disease from either clade of mpox.
Recommendations for health care providers:
- Any positive orthopoxvirus (OPXV), non-variola orthopoxvirus (NVO), or monkeypox virus (MPXV) result is sufficient for diagnosis of mpox. Do not await confirmatory or clade-specific testing.
- Clade determination does not impact clinical management nor plan of care.
- Please note: most commercial mpox testing is done via nonspecific assays (NVO, OPXV) and/or assays specific to clade II MPXV. A common result pairing is positive orthopoxvirus (+NVO or +OPXV) with a negative (clade II) MPXV--this indicates clade I mpox.
- Any positive result (OPXV, NVO, or MPXV) should continue to be reported to local public health per standard Title 17 reporting procedures.
- Reminder: Recommend two doses of mpox vaccine for patients at risk—see CDPH Mpox Vaccination Recommendations. Vaccination remains the best tool to reduce risk of infection and prevent severe disease from clade I and clade II mpox.
- JYNNEOS is safe for patients who are immunocompromised or who take immunosuppressants. It is also recommended for all patients with HIV. Vaccination is especially important to prevent severe mpox disease in these patients if they are at risk for mpox exposure.
- JYNNEOS vaccine is available at many chain pharmacies and local health departments.
- Based on available data, California Department of Public Health does not recommend JYNNEOS boosters (third doses) at this time.
- Reminder: Consider mpox as a differential diagnosis in sexually active patients with rash, lesion(s), or proctitis (PDF).
- Patients with a history of mpox infection or mpox vaccination may have more mild presentations.
- Follow infection control guidelines including wearing full PPE (gown, gloves, eyewear, well fitted N95 mask) when seeing patients with suspected mpox or cleaning patient rooms.
- Any patients being tested for mpox should be advised to isolate at home, away from others, pending results.
Resources for patients:
© 2026 Microsoft Dynamics. All rights reserved.
850 Marina Bay Parkway Building P, 2nd Floor Richmond, CA 94804
Unsubscribe